Somewhat Positive Media Coverage Somewhat Unlikely to Impact Galena Biopharma (GALE) Stock Price
News stories about Galena Biopharma (NASDAQ:GALE) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Galena Biopharma earned a news impact score of 0.25 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.4637061770453 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- A Few Clear Signs For Galena Biopharma, Inc. (GALE), ZIOPHARM Oncology, Inc. (ZIOP) – AllStockNews (allstocknews.com)
- Galena Biopharma Inc (GALE) Announces 2Q:17 Financial Results – Smarter Analyst (smarteranalyst.com)
- Galena Biopharma, Inc. (GALE): Trading Secrets for Today’s Investors – StockNewsGazette (stocknewsgazette.com)
- Galena Biopharma Inc (GALE) Announces Earnings Results (americanbankingnews.com)
- Sellas Life Sciences and Galena Biopharma plan merger (thepharmaletter.com)
Shares of Galena Biopharma (GALE) traded down 5.6521% on Monday, reaching $0.3205. 68,447 shares of the company traded hands. The stock’s market capitalization is $12.31 million. Galena Biopharma has a one year low of $0.26 and a one year high of $9.10. The stock’s 50 day moving average price is $0.52 and its 200-day moving average price is $0.62.
Galena Biopharma (NASDAQ:GALE) last posted its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.01. During the same period in the previous year, the firm earned $0.05 earnings per share. Equities analysts forecast that Galena Biopharma will post ($0.71) earnings per share for the current fiscal year.
A number of research firms have recently commented on GALE. ValuEngine lowered shares of Galena Biopharma from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Zacks Investment Research lowered shares of Galena Biopharma from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Galena Biopharma in a research note on Wednesday, August 9th.
About Galena Biopharma
Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.
Receive News & Stock Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related stocks with our FREE daily email newsletter.